Literature DB >> 24065086

Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection.

Biao Deng1, Xiao-Fei Zhang, Xu-Chao Zhu, Hua Huang, Hu-Liang Jia, Qing-Hai Ye, Qiong-Zhu Dong, Lun-Xiu Qin.   

Abstract

Osteopontin (OPN) may facilitate tumorigenesis and metastasis through prevention of tumor cells from apoptosis. Although previous studies have suggested involvement of enhanced Bcl-2 protein family expression, the role of OPN together with Bcl-2 in hepatocellular carcinoma (HCC) remains unknown. In this study, we used western blotting to detect the OPN and Bcl-2 expression levels in cell lines with different OPN backgrounds and HCC tissues, and tumor tissue microarrays to examine OPN and Bcl-2 expression levels in 454 HCC cases. The Kaplan-Meier method and log-rank test were applied to investigate the predictive values of OPN and Bcl-2 in HCC patients. In vitro assays indicated that OPN expression increased concordantly with increasing metastatic potential in MHCC97-H, MHCC97-L, HepG2 and SMMC-7721 cell lines by western blotting, whereas Bcl-2 expression declined. In addition, Bcl-2 was highly upregulated in OPN knockdown MHCC97-H cell lines. Furthermore, in HCC tissues, it was confirmed that OPN levels were also significantly higher in recurrent tumor tissues compared to non-recurrent tissues by western blotting (p<0.001), whereas the contrary occurred in Bcl-2 (p=0.046). Using immunohistochemistry analysis, patients with higher OPN levels had significantly shorter median survival time and recurrence time compared to the lower ones, although the opposite occurred in Bcl-2 levels. Of note, when OPN and Bcl-2 were combined, we found that the co-index of OPN/Bcl-2 was an independent prognostic factor for both overall survival (p<0.001) and time to recurrence (p<0.001). Our findings demonstrate that OPN/Bcl-2 expression is a promising independent predictor of recurrence and survival in HCC. Additionally, Bcl-2 levels may be regulated by OPN in the HCC microenvironment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24065086     DOI: 10.3892/or.2013.2737

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Silencing of ZNF139-siRNA induces apoptosis in human gastric cancer cell line BGC823.

Authors:  Liqiao Fan; Bibo Tan; Yong Li; Qun Zhao; Yü Liu; Dong Wang; Zhidong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 2.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

Review 3.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

4.  Inhibition of Vav3 gene can promote apoptosis of human gastric cancer cell line MGC803 by regulating ERK pathway.

Authors:  Bi-Bo Tan; Ming-Ming Zhang; Yong Li; Qun Zhao; Li-Qiao Fan; Yu Liu; Dong Wang
Journal:  Tumour Biol       Date:  2015-12-22

Review 5.  RNA splicing: a dual-edged sword for hepatocellular carcinoma.

Authors:  Anjali Kashyap; Greesham Tripathi; Avantika Tripathi; Rashmi Rao; Manju Kashyap; Anjali Bhat; Deepak Kumar; Anjali Rajhans; Pravindra Kumar; Darshan Shimoga Chandrashekar; Riaz Mahmood; Amjad Husain; Hatem Zayed; Alok Chandra Bharti; Manoj Kumar Kashyap
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

6.  Can combination of osteopontin and peritumor-infiltrating macrophages be a prognostic marker of early-stage hepatocellular carcinoma?

Authors:  Yoo Jin Lee; Byoung Kuk Jang
Journal:  Hepatobiliary Surg Nutr       Date:  2014-04       Impact factor: 7.293

7.  Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma.

Authors:  Kai-Qian Zhou; Wei-Feng Liu; Liu-Xiao Yang; Yun-Fan Sun; Jie Hu; Fei-Yu Chen; Cheng Zhou; Xiang-Yu Zhang; Yuan-Fei Peng; Lei Yu; Jian Zhou; Jia Fan; Zheng Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

8.  SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-κB signaling.

Authors:  Xuejiao Li; Zhongxiu Jiang; Xiangmin Li; Xiaoye Zhang
Journal:  Onco Targets Ther       Date:  2018-03-02       Impact factor: 4.147

9.  Bcl-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andropause-age patients.

Authors:  Xiao-Fei Zhang; Xin Yang; Hu-Liang Jia; Wen-Wei Zhu; Lu Lu; Wei Shi; Hao Zhang; Jin-Hong Chen; Yi-Feng Tao; Zheng-Xin Wang; Jun Yang; Lian-Xin Wang; Ming Lu; Yan Zheng; Jing Zhao; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Cancer Biol Med       Date:  2016-12       Impact factor: 4.248

10.  Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin.

Authors:  Qiongzhu Dong; Xuchao Zhu; Chun Dai; Xiaofei Zhang; Xiaomei Gao; Jinwang Wei; Yuanyuan Sheng; Yan Zheng; Jian Yu; Lu Xie; Yi Qin; Peng Qiao; Chuang Zhou; Xinxin Yu; Huliang Jia; Ning Ren; Haijun Zhou; Qinghai Ye; Lunxiu Qin
Journal:  Oncotarget       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.